Alzheimer’s is strongly associated with a build-up of proteins in the brain. These amyloid-beta proteins clump together into sticky plaques. These clumps disrupt communication between patients’ brain cells. This causes the cells to stop working and die off, accelerating patients’ cognitive decline. The new drug is called lecanemab and t’s designed to break down these protein deposits.